GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » Net Income

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Net Income : $1.34 Mil (TTM As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. OWC Pharmaceutical Research's Net Income for the three months ended in Sep. 2019 was $-0.29 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2019 was $1.34 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. OWC Pharmaceutical Research's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-0.00.


OWC Pharmaceutical Research Net Income Historical Data

The historical data trend for OWC Pharmaceutical Research's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research Net Income Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Net Income
Get a 7-Day Free Trial Premium Member Only -5.07 -1.66 -2.29 -4.56 -10.26

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.99 -5.08 -1.00 7.71 -0.29

OWC Pharmaceutical Research Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

OWC Pharmaceutical Research's Net Income for the fiscal year that ended in Dec. 2018 is calculated as

Net Income(A: Dec. 2018 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-10.258+0+0+0
=-10.26

OWC Pharmaceutical Research's Net Income for the quarter that ended in Sep. 2019 is calculated as

Net Income(Q: Sep. 2019 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.287+0+0+0
=-0.29

Net Income for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OWC Pharmaceutical Research  (OTCPK:OWCP) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

OWC Pharmaceutical Research's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2019 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


OWC Pharmaceutical Research Net Income Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Traded in Other Exchanges
N/A
Address
2 Ben Gurion Street, Ramat Gan, ISR, 5257334
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.
Executives
Asher Zwebner director, officer: CHIEF FINANCIAL OFFICER CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387